Iressa NDA Awaits CMC Data; Oncology Response Rates Under Scrutiny At FDA

FDA is looking carefully at response rates in assessing whether an endpoint demonstrates clinical benefit in oncology trials, Oncologic Drug Products Division Director Richard Pazdur, MD, said during the American Society of Clinical Oncology meeting in Orlando May 21